James Edgemond serves as the Chief Financial Officer and Treasurer at United Therapeutics Corporation, a position he has held since 2000. With a robust background in finance, Edgemond has been instrumental in guiding the company through significant growth and development. Before joining United Therapeutics, he worked at Ernst & Young LLP, where he honed his skills in auditing and financial management. His transition to United Therapeutics marked the beginning of a long and successful tenure, where he has played a key role in shaping the company's financial strategies. Under Edgemond's leadership, United Therapeutics has seen substantial financial success, with a focus on sustainable growth and innovation in the biotechnology sector. He has been pivotal in overseeing the company's financial planning, budgeting, and investor relations, ensuring that United Therapeutics remains at the forefront of the industry. His strategic vision has helped the company navigate complex financial landscapes and capitalize on emerging opportunities. Edgemond's contributions have been vital in maintaining the company's strong financial health and supporting its mission to develop innovative therapies for patients with chronic and life-threatening conditions. In addition to his role at United Therapeutics, Edgemond is known for his commitment to ethical financial practices and corporate governance. He has been recognized for his leadership and expertise in the financial sector, often speaking at industry conferences and contributing to discussions on financial strategy in biotechnology. His dedication to the company's values and his ability to drive financial performance have solidified his reputation as a respected leader in the field.